Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?

SIMPLE SUMMARY: The landscape of gastric cancer treatment has changed owing to the widespread use of immune checkpoint inhibitors. Only a subset of patients, though, have reaped substantial benefits. One of the crucial issues in current research is seeking efficacious biomarkers to identify favorabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yongqing, Hu, Pengbo, Xu, Liang, Zhang, Xiuyuan, Li, Zhou, Li, Yiming, Qiu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137150/
https://www.ncbi.nlm.nih.gov/pubmed/37190201
http://dx.doi.org/10.3390/cancers15082273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137150/
https://www.ncbi.nlm.nih.gov/pubmed/37190201
http://dx.doi.org/10.3390/cancers15082273

Ejemplares similares